{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:11:14Z","timestamp":1777378274517,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ajog.2020.09.045","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T03:14:33Z","timestamp":1601954073000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth"],"prefix":"10.1016","volume":"224","author":[{"given":"David B.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald D.","family":"McIntire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Leveno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2020.09.045_bib1","author":"Hamilton"},{"key":"10.1016\/j.ajog.2020.09.045_bib5","author":"Walker"},{"key":"10.1016\/j.ajog.2020.09.045_bib6","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0039-3400227","article-title":"17-OHPC to prevent recurrent preterm birth in\u00a0singleton gestations (PROLONG Study): a multicenter, international, randomized double-blinded trial","volume":"37","author":"Blackwell","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2020.09.045_bib10","doi-asserted-by":"crossref","first-page":"l6391","DOI":"10.1136\/bmj.l6391","article-title":"Preterm births: US panel recommends withdrawal of prevention drug in controversial vote","volume":"367","author":"Mahase","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2020.09.045_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40545-015-0046-2","article-title":"Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study","volume":"8","author":"Vitry","year":"2015","journal-title":"J\u00a0Pharm Policy Pract"},{"key":"10.1016\/j.ajog.2020.09.045_bib14","author":"Wesley"},{"key":"10.1016\/j.ajog.2020.09.045_bib15","author":"Wesley"},{"key":"10.1016\/j.ajog.2020.09.045_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajog.2013.04.027","article-title":"Progesterone is not the same as 17\u03b1-hydroxyprogesterone caproate: implications for obstetrical practice","volume":"208","author":"Romero","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2010.03.020","article-title":"Was the preterm birth rate in the placebo group too high in the Meis MFMU Network trial of 17-OHPC?","volume":"202","author":"Iams","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.0730-7659.2004.00315.x","article-title":"Progesterone and preterm: seventy years of \u201cd\u00e9j\u00e0 vu\u201d or \u201cstill to be seen\u201d?","volume":"31","author":"Keirse","year":"2004","journal-title":"Birth"},{"key":"10.1016\/j.ajog.2020.09.045_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1471-0528.1985.tb03071.x","article-title":"The repetition of spontaneous preterm labour","volume":"92","author":"Carr-Hill","year":"1985","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib20","first-page":"379","article-title":"Recurrence of preterm birth in singleton and twin pregnancies","volume":"98","author":"Bloom","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib21","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.ajog.2017.02.025","article-title":"17-alpha hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study","volume":"216","author":"Nelson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0037-1607317","article-title":"The effect of prior term birth on risk of recurrent spontaneous preterm birth","volume":"35","author":"Purisch","year":"2018","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2020.09.045_bib26","author":"Reuters"},{"key":"10.1016\/j.ajog.2020.09.045_bib27","author":"Lowe"},{"key":"10.1016\/j.ajog.2020.09.045_bib30","first-page":"4","article-title":"Gestational diabetes: detection, management, and implications","volume":"16","author":"Carr","year":"1998","journal-title":"Clin Diab"},{"key":"10.1016\/j.ajog.2020.09.045_bib31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajog.2019.05.033","article-title":"Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis","volume":"221","author":"Pergialiotis","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib32","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2337\/dc07-0564","article-title":"Increased incidence of gestational diabetes in women receiving prophylactic 17\u03b1-hydroxyprogesterone caproate for prevention of recurrent preterm delivery","volume":"30","author":"Rebarber","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2020.09.045_bib33","series-title":"Williams Obstetrics","year":"2018"},{"key":"10.1016\/j.ajog.2020.09.045_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/AOG.0000000000003991","article-title":"Re-examining\u00a0the Meis trial for evidence of false-positive results","volume":"136","author":"Sibai","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib35","author":"Nyugen"},{"key":"10.1016\/j.ajog.2020.09.045_bib36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ajog.2017.07.013","article-title":"Reply","volume":"217","author":"Nelson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib37","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine--reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib38","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2016.9125","article-title":"Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials","volume":"177","author":"Wallach","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/AOG.0b013e3182723b1b","article-title":"Practice Bulletin no. 130: prediction and prevention of preterm birth","volume":"120","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib41","doi-asserted-by":"crossref","first-page":"B16","DOI":"10.1016\/j.ajog.2020.04.001","article-title":"SMFM statement: use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth","volume":"223","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/AOG.0000000000003787","article-title":"Accelerated approval of 17\u03b1-hydroxyprogesterone caproate: a cautionary tale","volume":"135","author":"Godlewski","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib44","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib45","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2020.09.045_bib46","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with\u00a0or\u00a0without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2020.09.045_bib48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsps.2011.12.001","article-title":"The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)","volume":"20","author":"Sasich","year":"2012","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.ajog.2020.09.045_bib50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA approval and regulation of pharmaceuticals, 1983-2018","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2020.09.045_bib51","author":"Lu"},{"key":"10.1016\/j.ajog.2020.09.045_bib52","author":"Liss"},{"key":"10.1016\/j.ajog.2020.09.045_bib53","author":"Mueller"},{"key":"10.1016\/j.ajog.2020.09.045_bib57","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1097\/AOG.0b013e31821c2d75","article-title":"Unjusti\ufb01ed increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17\u03b1-hydroxyprogesterone caproate)","volume":"117","author":"Cohen","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib58","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jamainternmed.2017.5017","article-title":"Utilization, cost, and outcome of branded vs compounded 17-alpha hydroxyprogesterone caproate in prevention of preterm birth","volume":"177","author":"Fried","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ajog.2018.04.025","article-title":"Reply","volume":"219","author":"Nelson","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib60","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jama.2018.1150","article-title":"Health care spending in the United States and other high-income countries","volume":"319","author":"Papanicolas","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2020.09.045_bib61","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jama.2018.1151","article-title":"The real cost of the US health care system","volume":"319","author":"Emanuel","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2020.09.045_bib62","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1001\/jama.2018.1149","article-title":"Factors contributing to higher health care spending in the United States compared with other high-income countries","volume":"319","author":"Parente","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2020.09.045_bib70","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jama.2020.1486","article-title":"Confirmatory trial for drug to prevent preterm birth finds no benefit, so why\u00a0is\u00a0it\u00a0still prescribed?","volume":"323","author":"Rubin","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2020.09.045_bib71","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM200005183422009","article-title":"Is academic medicine for sale?","volume":"342","author":"Angell","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib72","unstructured":"Angell M. Big Pharma, Bad Medicine. Available at: http:\/\/bostonreview.net\/angell-big-pharma-bad-medicine. Accessed January 18, 2020."},{"key":"10.1016\/j.ajog.2020.09.045_bib73","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1056\/NEJM198010233031703","article-title":"The new medical-industrial complex","volume":"303","author":"Relman","year":"1980","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib74","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ajog.2017.04.018","article-title":"Clinical trials and tribulations: 17OHPC and preventing recurrent preterm birth","volume":"216","author":"Young","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib75","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib76","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/sim.6825","article-title":"Exposure-wide epidemiology: revisiting Bradford Hill","volume":"35","author":"Ioannidis","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib77","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ajog.2017.11.582","article-title":"Reply","volume":"218","author":"Nelson","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib78","first-page":"S422","article-title":"703: recurrent spontaneous preterm birth risk is not associated with 17-alpha hydroxyprogesterone caproate levels","volume":"218","author":"Downes","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib79","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ajog.2017.03.014","article-title":"The importance of publishing trials with negative results","volume":"216","author":"Nygaard","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.09.045_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-060309-164311","article-title":"Role of postmarketing surveillance in contemporary medicine","volume":"62","author":"Woodcock","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hast.779","article-title":"Real-world evidence, public participation, and the FDA","volume":"47","author":"Schwartz","year":"2017","journal-title":"Hastings Cent Rep"},{"key":"10.1016\/j.ajog.2020.09.045_bib83","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2020.09.045_bib84","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.ajog.2020.09.045_bib85","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1471-0528.1990.tb01740.x","article-title":"Progestogen administration in pregnancy may prevent preterm delivery","volume":"97","author":"Keirse","year":"1990","journal-title":"Br J Obstet Gynaecol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820311686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820311686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:30:49Z","timestamp":1757590249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937820311686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0002937820311686"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2020.09.045","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2020.09.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}